Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
Technological advances allow use of mid-infrared spectroscopy for therapeutic drug monitoring
, /in Featured Articles, Therapeutic Drug Monitoring /by panglobalTherapeutic drug monitoring is used for a number of reasons. The usual techniques include immunoassay and mass spectrometry, both of which have limitations. CLI chatted to Dr Pin Dong (University of York, York, UK) to discuss the potential for Fourier transform infrared spectroscopy to bridge the gap and provide high specificity measurements with a fast […]
Revvity’s new automated free testosterone assay receives FDA clearance
, /in Product News /by panglobalRevvity Inc has announced FDA 510(k) clearance for EUROIMMUN’s automated chemilumin-escence immunoassay (ChLIA) for direct quantitative measurement of free testosterone. The assay, which runs on the company’s iSYS and i10 platforms, represents the first FDA-cleared automated direct measurement method for free testosterone in human serum or plasma.
Sapio Sciences expands laboratory informatics capabilities
, /in Product News /by panglobalLaboratory software provider Sapio Sciences has announced significant updates to its informatics platform, enhancing functionality across chemistry, immunogenicity, GMP workflows and molecular biology. Release 24.12 introduces automated validation tools and refined chemistry representation capabilities, aimed at improving laboratory efficiency and data management.
Thermo Fisher unveils DNA/RNA extraction kit for haematological cancer research
, /in Product News /by panglobalA new sequential DNA/RNA isolation kit has been launched by Thermo Fisher Scientific, designed to streamline genomic analysis workflows in haematological cancer research. The MagMAX Sequential DNA/RNA kit enables concurrent extraction of DNA and RNA from a single sample, potentially accelerating research into blood-based malignancies.
Serum Amyloid A (SAA) nephelometric and turbidimetric assays
, /in Product News /by panglobalTRIMERO Diagnostics offers assays for testing Serum Amyloid A (SAA) on Beckman Coulter’s IMMAGE® Immunochemical Systems and Clinical Chemistry Analyzers.
Johnson & Johnson acquires lumateperone developer in £14.6bn deal
, /in E-News /by panglobalJohnson & Johnson (J&J) has announced the acquisition of Intra-Cellular Therapies for $14.6 billion, marking a significant expansion of its neuroscience portfolio. The deal centres on CAPLYTA (lumateperone), a novel antipsychotic with a distinctive pharmacological profile characterised by high serotonin 5-HT2A receptor occupancy combined with lower dopamine D2 receptor binding at therapeutic doses.
PrecisionLife advances diagnostic strategy with new chief commercial officer appointment
, /in E-News /by panglobalPrecisionLife has appointed Bill Keating as chief commercial officer for diagnostics and healthcare, marking a significant step in the company’s expansion of its Mechanostic testing platform for complex chronic diseases. The Oxford-based precision medicine company announced the appointment on 8 January 2025, signalling an intensified focus on commercialising its non-invasive genotypic testing capabilities.
Revvity partners with Element Biosciences to develop sequencing-based IVD neonatal screening
, /in E-News /by panglobalRevvity Inc. has announced a strategic partnership with Element Biosciences Inc. to develop and commercialise an in vitro diagnostic (IVD) workflow solution for neonatal sequencing. The collaboration builds upon Revvity’s existing next-generation sequencing (NGS) workflow for newborn sequencing research and aims to strengthen Element’s regulatory approval pathway for their AVITI benchtop sequencing system.
Roche acquires allogeneic CAR-T developer Poseida Therapeutics for $1.5bn
, /in E-News /by panglobalRoche has announced a definitive merger agreement to acquire the San Diego-based clinical-stage biopharmaceutical company Poseida Therapeutics, marking a significant expansion of its cell therapy portfolio. The acquisition, valued at up to US$1.5 billion, builds upon an existing partnership established in 2022 and aims to accelerate the development of off-the-shelf CAR-T cell therapies.
Leica Biosystems invests in Indica Labs to advance AI-powered digital pathologyIBA Lifesciences acquisition
, /in E-News /by panglobalLeica Biosystems has announced a significant strategic investment in artificial intelligence (AI) specialist Indica Labs, marking a pivotal advancement in digital pathology. The collaboration, announced on 8 January 2025, aims to accelerate the development of AI-enabled companion diagnostics (CDx) and enhance the detection of complex biomarker expression profiles that exceed human visual capabilities.